3D Cell Encapsulation Assembly for High-Dose Immune Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell encapsulation devices face challenges in efficiently delivering a large therapeutic dose of cells while minimizing the device's footprint and preventing immune system rejection, particularly for applications like diabetes treatment where continuous cell function is required.
Innovation Solution
A 3-dimensional large capacity cell encapsulation device with multiple chambers and a semi-permeable membrane that allows nutrient exchange and immune isolation, featuring a folded configuration for reduced footprint and a semi-permeable membrane to prevent immune system interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a large number of cells are encapsulated in a single device, then the therapeutic dose is sufficient, but the device footprint becomes too large for implantation
Solution Approach 1:
The device is divided into multiple discrete chambers (e.g., 8 chambers) that can be individually filled with cells. Each chamber acts as an independent encapsulation unit, allowing the total cell dose to be distributed across multiple compartments rather than requiring a single large volume, thus reducing the overall device footprint while maintaining sufficient therapeutic cell quantity.
Solution Approach 2:
Multiple chambers are arranged in a nested or compact configuration where smaller chambers are positioned within or adjacent to each other in a space-efficient manner. This nesting approach maximizes the cell-containing volume within a minimized external footprint, enabling high cell density packaging without increasing the implantable device size.
2Area of stationary object
If the device is made flat for easy implantation, then the footprint is small, but the cell exchange efficiency with surrounding tissue is reduced
Solution Approach 1:
The device transitions from a two-dimensional flat structure to a three-dimensional configuration with multiple elevated and recessed chambers. This dimensional change creates increased surface area and volume for cell encapsulation while maintaining a compact footprint. The 3D chamber structures provide enhanced contact area with surrounding tissue for improved nutrient and oxygen exchange efficiency.
3Ease of manufacture
If the device structure is simplified for manufacturing, then the manufacturing process is easier, but the device cannot provide adequate immune isolation
Solution Approach 1:
Each chamber is encapsulated by a semi-permeable membrane that acts as a flexible barrier between the encapsulated cells and the host immune system. These thin film membranes provide effective immune isolation while allowing passive diffusion of nutrients and waste products. The membrane structure is simple to integrate into the chamber design and manufacture, maintaining ease of fabrication while ensuring adequate immune protection.
4Quantity of substance
If multiple chambers are added to increase cell capacity, then the cell dose is sufficient, but the device complexity increases
Solution Approach 1:
Multiple chambers are merged into a single integrated device structure with shared walls and common manufacturing processes. The chambers are designed with uniform geometry and standardized interfaces, allowing them to be fabricated as a single piece or pre-assembled modules. This merging approach increases cell capacity through multiple compartments while minimizing the complexity increase by using repetitive, standardized design elements throughout the device.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device effectively delivers a high cell dose with minimal extrusion and maintains cell function by providing a protective barrier against the immune system, allowing for continuous therapeutic output without the need for immunosuppression.
Implementation Method 1
The device is comprised of a biocompatible, semipermeable polymer that is substantially free of cellulose and allows for the passive diffusion of oxygen and nutrients to the encapsulated cells while preventing the infiltration of immune system cells
Implementation Method 2
The luminal matrix is any biostable agent that functions as a conduit and provides and increases the flow of oxygen and nutrients to the encapsulated cells, thereby promoting cell survival in the short and long term post implantation
Data Source
AI summary
Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.